Univax Biologics
Executive Summary
Postpones planned 2.5 mil. share offering after "a significant amount of uncertainty in the market for biotechnology stocks has forced down the price of Univax' stock to an unacceptable level," Rockville, Md.-based firm announces Feb. 1. Univax, with more than $30 mil. in cash resources, may proceed with the offering "if conditions improve".